Full Name
Ooi Gaik Ming, Melissa
Main Affiliation
 
 
Email
mdcogmm@nus.edu.sg
 

Publications

Results 1-7 of 7 (Search time: 0.009 seconds).

Issue DateTitleAuthor(s)
120-Sep-2018Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosisTeoh, Phaik Ju ; An, Omer ; Chung, Tae-Hoon ; Chooi, Jing Yuan ; Toh, Sabrina HM ; Fan, Shuangyi ; Wang, Wilson ; Koh, Bryan TH; Fullwood, Melissa J ; Ooi, Melissa G ; de Mel, Sanjay; Soekojo, Cinnie Y; Chen, Leilei ; Ng, Siok Bian ; Yang, Henry ; Chng, Wee Joo 
21-Mar-2021Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysisChong, Lip Leong; Soon, Yu Yang ; Soekojo, Cinnie Yentia; Ooi, Melissa ; Chng, Wee Joo ; de Mel, Sanjay
32011Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: Implications for clinical translationMcMillin D.W.; Delmore J.; Negri J.; Ooi M. ; Klippel S.; Miduturu C.V.; Gray N.S.; Richardson P.G.; Anderson K.C.; Kung A.L.; Mitsiades C.S.
43-Sep-2021A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)Chen, Yunxin ; Gopalakrishnan, Sathish Kumar; Ooi, Melissa ; Sultana, Rehena ; Lim, Li Hui; Grigoropoulos, Nicholas ; Ong, Shin Yeu ; Xu, Mingge; Chng, Wee Joo ; Goh, Yeow Tee ; Nagarajan, Chandramouli
52018Potential clinical application of genomics in multiple myelomaSoekojo, C.Y; de Mel, S; Ooi, M ; Yan, B; Chng, W.J 
62020Relationship of JAK2 (V617F) allelic burden with clinico-haematological manifestations of philadelphia-negative myeloproliferative neoplasmsYow, K.S.; Liu, X.; Chai, C.N.; Tung, M.L. ; Yan, B.; Christopher, D.; Ong, K.H.; Ooi, M.G. 
72016Thrombotic microangiopathy during carfilzomib use: case series in SingaporeChen, Y; Ooi, M. ; Lim, S.F; Lin, A; Lee, J; Nagarajan, C; Phipps, C; Lee, Y.S; Grigoropoulos, N.F ; Lao, Z ; Surendran, S; Teh, E.M; Goh, Y.T ; Chng, W.J ; Gopalakrishnan, S.K